成纤维细胞生长因子受体信号传导作为胃癌的治疗靶点
Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer.
作者信息
Yashiro Masakazu, Matsuoka Tasuku
机构信息
Masakazu Yashiro, Tasuku Matsuoka, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
出版信息
World J Gastroenterol. 2016 Feb 28;22(8):2415-23. doi: 10.3748/wjg.v22.i8.2415.
Abstract
Fibroblast growth factor receptors (FGFRs) regulate a variety of cellular functions, from embryogenesis to adult tissue homeostasis. FGFR signaling also plays significant roles in the proliferation, invasion, and survival of several types of tumor cells. FGFR-induced alterations, including gene amplification, chromosomal translocation, and mutations, have been shown to be associated with the tumor initiation and progression of gastric cancer, especially in diffuse-type cancers. Therefore, the FGFR signaling pathway might be one of the therapeutic targets in gastric cancer. This review aims to provide an overview of the role of FGFR signaling in tumorigenesis, tumor progression, proliferation, and chemoresistance. We also discuss the accumulating evidence that demonstrates the effectiveness of using clinical therapeutic agents to inhibit FGFR signaling for the treatment of gastric cancer.
摘要
成纤维细胞生长因子受体（FGFRs）调节多种细胞功能，从胚胎发生到成体组织稳态。FGFR信号传导在几种类型肿瘤细胞的增殖、侵袭和存活中也发挥着重要作用。FGFR诱导的改变，包括基因扩增、染色体易位和突变，已被证明与胃癌的肿瘤发生和进展相关，尤其是在弥漫型癌症中。因此，FGFR信号通路可能是胃癌的治疗靶点之一。本综述旨在概述FGFR信号传导在肿瘤发生、肿瘤进展、增殖和化疗耐药中的作用。我们还讨论了越来越多的证据，这些证据表明使用临床治疗药物抑制FGFR信号传导治疗胃癌的有效性。
相似文献
1
Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer.成纤维细胞生长因子受体信号传导作为胃癌的治疗靶点
World J Gastroenterol. 2016 Feb 28;22(8):2415-23. doi: 10.3748/wjg.v22.i8.2415.
2
FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.成纤维细胞生长因子受体融合在癌症中的作用：从诊断方法到治疗干预。
Int J Mol Sci. 2020 Sep 18;21(18):6856. doi: 10.3390/ijms21186856.
3
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.富替替尼是一种新型不可逆 FGFR1-4 抑制剂，对 FGFR 失调肿瘤具有选择性抗肿瘤活性。
Cancer Res. 2020 Nov 15;80(22):4986-4997. doi: 10.1158/0008-5472.CAN-19-2568. Epub 2020 Sep 24.
4
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.一项转化性临床试验中的高水平克隆性FGFR扩增及对FGFR抑制的反应
Cancer Discov. 2016 Aug;6(8):838-851. doi: 10.1158/2159-8290.CD-15-1246. Epub 2016 May 13.
5
FGFR-targeted therapeutics for the treatment of breast cancer.用于治疗乳腺癌的成纤维细胞生长因子受体（FGFR）靶向疗法。
Expert Opin Investig Drugs. 2017 Mar;26(3):303-311. doi: 10.1080/13543784.2017.1287173. Epub 2017 Feb 6.
6
Advances and challenges in targeting FGFR signalling in cancer.靶向癌症中 FGFR 信号的进展与挑战。
Nat Rev Cancer. 2017 May;17(5):318-332. doi: 10.1038/nrc.2017.8. Epub 2017 Mar 17.
7
Small molecule inhibition of fibroblast growth factor receptors in cancer.小分子抑制癌症中的成纤维细胞生长因子受体。
Cytokine Growth Factor Rev. 2013 Oct;24(5):467-75. doi: 10.1016/j.cytogfr.2013.05.002. Epub 2013 Jul 2.
8
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.针对乳腺癌中成纤维细胞生长因子受体信号传导的理论依据。
Breast Cancer Res Treat. 2015 Feb;150(1):1-8. doi: 10.1007/s10549-015-3301-y. Epub 2015 Feb 13.
9
Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.成纤维细胞生长因子（FGFs）在癌症中的意义：从预后到治疗应用。
Curr Drug Targets. 2019;20(8):852-870. doi: 10.2174/1389450120666190112145409.
10
Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.成纤维细胞生长因子（FGF）受体/FGF抑制剂：实体瘤反应优化的新靶点与策略
Semin Oncol. 2015 Dec;42(6):801-19. doi: 10.1053/j.seminoncol.2015.09.027. Epub 2015 Sep 24.
引用本文的文献
1
Gastric Cancer Genetics and Its Implications for Diagnosis, Prognosis, and Treatment of the Disease.胃癌遗传学及其对该疾病诊断、预后和治疗的意义。
Korean J Helicobacter Up Gastrointest Res. 2024 Jun;24(2):103-112. doi: 10.7704/kjhugr.2024.0018. Epub 2024 Jun 10.
2
Single-cell RNA-seq reveals as a prognostic biomarker in low-grade endometrial stromal sarcoma.单细胞RNA测序揭示了[具体内容]作为低级别子宫内膜间质肉瘤的一种预后生物标志物。 （注：原文中“reveals”后缺少具体内容，翻译时根据语境补充了“[具体内容]”）
Front Immunol. 2024 Nov 29;15:1513076. doi: 10.3389/fimmu.2024.1513076. eCollection 2024.
3
Potential diagnostic, prognostic, and predictive biomarkers of gastric cancer.胃癌潜在的诊断、预后和预测生物标志物。
Health Sci Rep. 2024 Jul 21;7(7):e2261. doi: 10.1002/hsr2.2261. eCollection 2024 Jul.
4
Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer.晚期胃癌中人类表皮生长因子受体2阳性的靶向治疗进展
World J Gastrointest Oncol. 2024 Jun 15;16(6):2318-2334. doi: 10.4251/wjgo.v16.i6.2318.
5
Molecular pathways and therapeutic strategies in dermatofibrosarcoma protuberans (DFSP): unravelling the tumor's genetic landscape.隆突性皮肤纤维肉瘤（DFSP）的分子途径和治疗策略：解析肿瘤的基因图谱
EXCLI J. 2024 May 14;23:727-762. doi: 10.17179/excli2024-7164. eCollection 2024.
6
High-throughput computational screening and evaluation identifies 5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione (C3), as a novel EGFR-HER2 dual inhibitor in gastric tumors.高通量计算筛选和评估鉴定出 5-(4-氧代-4H-3,1-苯并恶嗪-2-基)-2-[3-(4-氧代-4H-3,1-苯并恶嗪-2-基)苯基]-1H-异吲哚-1,3(2H)-二酮（C3），作为一种新型的胃癌中 EGFR-HER2 双重抑制剂。
Oncol Res. 2023 Dec 28;32(2):251-259. doi: 10.32604/or.2023.043139. eCollection 2023.
7
Insights into the Relationship between Pentraxin-3 and Cancer.Pentraxin-3 与癌症关系的研究进展。
Int J Mol Sci. 2022 Dec 4;23(23):15302. doi: 10.3390/ijms232315302.
8
Peritoneal Seeding Is More Common in Gastric Cancer Patients with FGFR2 Amplification or High Tumor Mutation Burden.腹膜种植在伴有FGFR2扩增或高肿瘤突变负荷的胃癌患者中更为常见。
Diagnostics (Basel). 2022 Sep 28;12(10):2355. doi: 10.3390/diagnostics12102355.
9
Receptor Tyrosine Kinases Amplified in Diffuse-Type Gastric Carcinoma: Potential Targeted Therapies and Novel Downstream Effectors.弥漫型胃癌中扩增的受体酪氨酸激酶：潜在的靶向治疗和新型下游效应器
Cancers (Basel). 2022 Aug 1;14(15):3750. doi: 10.3390/cancers14153750.
10
Issues of origin, morphology and clinical significance of tumor microvessels in gastric cancer.胃癌肿瘤微血管的起源、形态及其临床意义。
World J Gastroenterol. 2021 Dec 28;27(48):8262-8282. doi: 10.3748/wjg.v27.i48.8262.
本文引用的文献
1
Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.成纤维细胞生长因子受体4蛋白表达与胃癌的临床病理特征
World J Gastroenterol. 2015 Feb 14;21(6):1838-44. doi: 10.3748/wjg.v21.i6.1838.
2
Current status of novel agents in advanced gastroesophageal adenocarcinoma.晚期胃食管腺癌新型药物的现状
J Gastrointest Oncol. 2015 Feb;6(1):60-74. doi: 10.3978/j.issn.2078-6891.2014.098.
3
Twist1 correlates with poor differentiation and progression in gastric adenocarcinoma via elevation of FGFR2 expression.Twist1通过提高FGFR2表达水平与胃腺癌的低分化和进展相关。
World J Gastroenterol. 2014 Dec 28;20(48):18306-15. doi: 10.3748/wjg.v20.i48.18306.
4
Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.转移性肿瘤演变和类器官建模表明，转化生长因子β受体2（TGFBR2）是弥漫性胃癌的癌症驱动因素。
Genome Biol. 2014 Aug 27;15(8):428. doi: 10.1186/s13059-014-0428-9.
5
Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.帕唑帕尼，一种新型的多靶点激酶抑制剂，在具有 FGFR2 扩增的胃癌细胞系中显示出强大的体外抗肿瘤活性。
Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23.
6
Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.多色荧光原位杂交揭示胃癌中相互排斥的 FGFR2、HER2 和 KRAS 基因扩增。
Cancer Lett. 2014 Oct 28;353(2):167-75. doi: 10.1016/j.canlet.2014.07.021. Epub 2014 Jul 30.
7
Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer.成纤维细胞生长因子受体1、2和4共过表达在胃癌中的预后意义
Mol Clin Oncol. 2014 Jul;2(4):509-517. doi: 10.3892/mco.2014.293. Epub 2014 May 15.
8
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.HER2、MET和FGFR2致癌驱动基因改变为胃癌的靶向治疗定义了不同的分子亚群。
Br J Cancer. 2014 Mar 4;110(5):1169-78. doi: 10.1038/bjc.2014.61. Epub 2014 Feb 11.
9
FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.FGFR2、HER2 和 cMet 在胃腺癌中的表达：检测、预后意义及下游通路激活评估。
Virchows Arch. 2014 Feb;464(2):145-56. doi: 10.1007/s00428-013-1517-y. Epub 2013 Dec 4.
10
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.FGFR 通路中的基因组畸变：实体瘤靶向治疗的机遇
Ann Oncol. 2014 Mar;25(3):552-563. doi: 10.1093/annonc/mdt419. Epub 2013 Nov 20.
Zotero 插件